Majuven

Majuven is a venture capital firm based in Singapore, specializing in early and growth-stage investments across biotech, fintech, and consumer tech sectors. Founded by experienced business leaders, Majuven focuses on backing companies that are at the forefront of disruptive and evolving trends. They typically invest in firms that have embarked on clear monetization strategies, ranging from seed to Series B rounds. Notable investments include Eureka Therapeutics, which develops monoclonal antibodies for cancer immunotherapy, and New Horizon Health, known for its colorectal cancer detection products. Majuven leverages its extensive network across Asia to support its portfolio companies in their regionalization efforts, providing both strategic guidance and access to crucial market channels. The firm’s leadership team is distinguished by its deep industry expertise. Founding and Managing Partner Lim Ho Kee has held executive positions at UBS AG and SingTel, among others. Founding Partner Prof. Low Teck Seng is a prominent figure in Singapore's research and innovation landscape, currently serving as CEO at the National Research Foundation. Another key figure, Lu Yoh Chie, is the founder of Biosensors International Group and has over 30 years of experience in the medical industry. Majuven’s investment strategy emphasizes long-term value creation and operational efficiency, making them a vital partner for startups looking to scale in the high-tech segments of healthcare, financial services, and digital consumerism.